161 related articles for article (PubMed ID: 37904542)
1. Valganciclovir modulates the tumor necrosis factor axis molecules expression and CD4+ T-cell subsets in disseminated Kaposi Sarcoma patients.
Ramon-Luing LA; Flores-Gonzalez J; Angel García-Rojas L; Islas-Muñoz B; Volkow-Fernández P; Chavez-Galan L
Clin Exp Immunol; 2024 Feb; 215(2):190-201. PubMed ID: 37904542
[TBL] [Abstract][Full Text] [Related]
2. Valganciclovir as Add-On Therapy Modifies the Frequency of NK and NKT Cell Subpopulations in Disseminated Kaposi Sarcoma Patients.
Flores-Gonzalez J; Ramon-Luing LA; Ocaña-Guzman R; Buendia-Roldan I; Islas-Muñoz B; Volkow-Fernández P; Chavez-Galan L
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053573
[TBL] [Abstract][Full Text] [Related]
3. Impact of valganciclovir therapy on severe IRIS-Kaposi Sarcoma mortality: An open-label, parallel, randomized controlled trial.
Volkow P; Chavez Galan L; Ramon-Luing L; Cruz-Velazquez J; Cornejo-Juarez P; Sada-Ovalle I; Perez-Padilla R; Islas-Muñoz B;
PLoS One; 2023; 18(5):e0280209. PubMed ID: 37195970
[TBL] [Abstract][Full Text] [Related]
4. Dysregulation of membrane-bound tumor necrosis factor-alpha and tumor necrosis factor receptors on mononuclear cells in human immunodeficiency virus type 1 infection: low percentage of p75-tumor necrosis factor receptor positive cells in patients with advanced disease and high viral load.
Hestdal K; Aukrust P; Müller F; Lien E; Bjerkeli V; Espevik T; Frøland SS
Blood; 1997 Oct; 90(7):2670-9. PubMed ID: 9326234
[TBL] [Abstract][Full Text] [Related]
5. Immunophenotypic analysis in participants with Kaposi sarcoma following pomalidomide administration.
Lurain K; Polizzotto MN; Krug LT; Shoemaker G; Singh A; Jensen SMR; Wyvill KM; Ramaswami R; Uldrick TS; Yarchoan R; Sereti I
AIDS; 2023 Sep; 37(11):1693-1703. PubMed ID: 37352498
[TBL] [Abstract][Full Text] [Related]
6. Differential effect of human herpesvirus 6A on cell division and apoptosis among naive and central and effector memory CD4+ and CD8+ T-cell subsets.
Gupta S; Agrawal S; Gollapudi S
J Virol; 2009 Jun; 83(11):5442-50. PubMed ID: 19297473
[TBL] [Abstract][Full Text] [Related]
7. GB virus C infection is associated with altered lymphocyte subset distribution and reduced T cell activation and proliferation in HIV-infected individuals.
Stapleton JT; Chaloner K; Martenson JA; Zhang J; Klinzman D; Xiang J; Sauter W; Desai SN; Landay A
PLoS One; 2012; 7(11):e50563. PubMed ID: 23209780
[TBL] [Abstract][Full Text] [Related]
8. Multifunctional, TNF-α and IFN-γ-Secreting CD4 and CD8 T Cells and CD8
Rodrigues LS; Barreto AS; Bomfim LGS; Gomes MC; Ferreira NLC; da Cruz GS; Magalhães LS; de Jesus AR; Palatnik-de-Sousa CB; Corrêa CB; de Almeida RP
Front Immunol; 2021; 12():773983. PubMed ID: 34777391
[TBL] [Abstract][Full Text] [Related]
9. The effects of human herpesvirus 8 infection and interferon-gamma response in cutaneous lesions of Kaposi sarcoma differ among human immunodeficiency virus-infected and uninfected individuals.
Guedes F; de Andrade HF; Fernandes ER; Tuon FF; Brasil RA; Pagliari C; Duarte MI
Br J Dermatol; 2008 Sep; 159(4):839-46. PubMed ID: 18644020
[TBL] [Abstract][Full Text] [Related]
10. Association of CD8+ T lymphocyte subsets with the most commonly used markers to monitor HIV type 1 infection in children treated with highly active antiretroviral therapy.
Navarro J; Resino S; Bellón JM; Abad ML; Gurbindo D; Fernández-Cruz E; Muñóz-Fernández MA
AIDS Res Hum Retroviruses; 2001 Apr; 17(6):525-32. PubMed ID: 11350666
[TBL] [Abstract][Full Text] [Related]
11. Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience.
Gray CM; Schapiro JM; Winters MA; Merigan TC
AIDS Res Hum Retroviruses; 1998 May; 14(7):561-9. PubMed ID: 9591710
[TBL] [Abstract][Full Text] [Related]
12. A Randomized Placebo-Controlled Efficacy Study of a Prime Boost Therapeutic Vaccination Strategy in HIV-1-Infected Individuals: VRI02 ANRS 149 LIGHT Phase II Trial.
Lévy Y; Lacabaratz C; Lhomme E; Wiedemann A; Bauduin C; Fenwick C; Foucat E; Surenaud M; Guillaumat L; Boilet V; Rieux V; Bouchaud O; Girard PM; Molina JM; Morlat P; Hocqueloux L; Richert L; Pantaleo G; Lelièvre JD; Thiébaut R
J Virol; 2021 Apr; 95(9):. PubMed ID: 33568510
[TBL] [Abstract][Full Text] [Related]
13. Kaposi sarcoma in people living with HIV: incidence and associated factors in a French cohort between 2010 and 2015.
Poizot-Martin I; Lions C; Cheret A; Rey D; Duvivier C; Jacomet C; Allavena C; Huleux T; Bani-Sadr F; Obry-Roguet V; Makinson A;
AIDS; 2020 Mar; 34(4):569-577. PubMed ID: 31764070
[TBL] [Abstract][Full Text] [Related]
14. CD4(+) T-cell immunodeficiency is more dependent on immune activation than viral load in HIV-infected children on highly active antiretroviral therapy.
Resino S; Seoane E; Gutiérrez MD; León JA; Muñoz-Fernández MA
J Acquir Immune Defic Syndr; 2006 Jul; 42(3):269-76. PubMed ID: 16810122
[TBL] [Abstract][Full Text] [Related]
15. A novel mathematical model of AIDS-associated Kaposi's sarcoma: Analysis and optimal control.
Kaondera-Shava RF; Lungu E; Szomolay B
Biosystems; 2021 Feb; 200():104318. PubMed ID: 33309554
[TBL] [Abstract][Full Text] [Related]
16. [Dynamic analysis of tuberculosis specific mononuclear cells in peripheral blood of HIV patients with tuberculosis].
Zou S; Zhu Q; Guo YN; Xiang PZ; Mo GL; Chen JH; Liu K; Liang K
Zhonghua Jie He He Hu Xi Za Zhi; 2022 Nov; 45(11):1109-1116. PubMed ID: 36344228
[No Abstract] [Full Text] [Related]
17. [Abnormal Activation of T Cells in HIV-1 Infection After Antiretroviral Therapy].
Guo Y; Zhang YL; Zhu D; Gong FH; Gao YS; Zhu KR; Li SS
Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 Mar; 54(2):415-421. PubMed ID: 36949708
[TBL] [Abstract][Full Text] [Related]
18. Immune modulatory effects of cyclooxygenase type 2 inhibitors in HIV patients on combination antiretroviral treatment.
Kvale D; Ormaasen V; Kran AM; Johansson CC; Aukrust P; Aandahl EM; Frøland SS; Taskén K
AIDS; 2006 Apr; 20(6):813-20. PubMed ID: 16549964
[TBL] [Abstract][Full Text] [Related]
19. Differential upregulation of CD38 on different T-cell subsets may influence the ability to reconstitute CD4+ T cells under successful highly active antiretroviral therapy.
Benito JM; López M; Lozano S; Ballesteros C; Martinez P; González-Lahoz J; Soriano V
J Acquir Immune Defic Syndr; 2005 Apr; 38(4):373-81. PubMed ID: 15764953
[TBL] [Abstract][Full Text] [Related]
20. Kaposi sarcoma herpes virus antibody response and viremia following highly active antiretroviral therapy in the Swiss HIV Cohort study.
Sullivan SG; Hirsch HH; Franceschi S; Steffen I; Amari EB; Mueller NJ; Magouras I; Biggar RJ; Rickenbach M; Clifford GM;
AIDS; 2010 Sep; 24(14):2245-52. PubMed ID: 20543658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
